Hormonal management of abnormal uterine bleeding

Clinical Obstetrics and Gynecology

Volumn 48, Issue 2, 2005, Pages 337-352

  Singh, Rameet H ^a   Blumenthal, Paul ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; DANAZOL; ESTROGEN; FLURBIPROFEN; GESTAGEN; GONADORELIN DERIVATIVE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TAMOXIFEN; TRANEXAMIC ACID;

ABDOMINAL PAIN; ACNE; ANOVULATION; BODY WEIGHT DISORDER; BREAST TENDERNESS; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; ENDOMETRIUM ABLATION; FEMALE; HEADACHE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; MASTALGIA; MENORRHAGIA; META ANALYSIS; NAUSEA; OVARY CYST; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UTERUS BLEEDING;

CONTRACEPTIVE AGENTS, FEMALE; DANAZOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEVONORGESTREL; PROGESTERONE; PROGESTERONE CONGENERS; UTERINE HEMORRHAGE;

EID: 18044363455     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.grf.0000159540.11974.17     Document Type: Review

References (89)

1. Gaufriez A. Menstrual disorders in adolescence: pathophysiology and treatment. Horm Res. 1991;36:156-159.
2. Cohen BJ, Gibor Y. Anemia and menstrual blood loss. Obstet Gynecol Surv. 1980;35:597-618.
3. Mishell DR, Stenchever M, Droegemuelle W, et al. Comprehensive Gynecology. 3rd ed. St. Louis, MO: Mosby-Year Book, Inc; 1997.
4. Cole SK, Billewicz WZ, Thomson AM. Sources of variation in menstrual blood loss. J Obstet Gynaecol Br Commonw. 1971;78:933.
5. Hallberg L, Högdahl AM, Nilsson L, et al. Menstrual blood loss-a population study: variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45(3):320-351.
6. Newton J, Barnard G, Collins W. A rapid method for measuring menstrual blood loss using automatic extraction. Contraception. 1977;16:269.
7. Van Eijkeren MA, Scholten PC, Christiaens GC, et al. The alkaline hematin method for measuring menstrual blood loss-a modification and its clinical use in menorrhagia. Eur J Obstet Gynecol Reprod Biol. 1986;22:345.
8. Fraser IS, McCarron G, Markham R, et al. Blood and fluid content of menstrual discharge. Obstet Gynecol. 1985;65:194-198.
9. Chimbira TH, Anderson ABM, Turnbull AC. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. Br J Obstet Gynaecol. 1980;87:603-609.
10. Mishell D. Medical approach to managing abnormal uterine bleeding. Presented at: Women's Healthcare: From Adolescence Through Menopause; January 31, 2004; Boston, Massachusetts.
11. Fraser IS, Hickey M, Song JY. A comparison of mechanisms underlying disturbances of bleeding caused by spontaneous dysfunctional uterine bleeding or hormonal contraception. Hum Reprod. 1996;11:165-178.
12. Beilby JOW, Farrer-Brown G, Tarbit MH. The microvasculature of common uterine abnormalities, other than fibroids. J Obstet Gynaecol Br Commonw. 1971;78:361-368.
13. Christiaens GC, Sixma JJ, Haspels AA. Morphology of haemostasis in menstrual endometrium. Br J Obstet Gynaecol. 1980;87:425.
14. Rees MCP, Cederholm-Williams SA, Turnbull AC. Coagulation factors and fibrinolytic proteins in menstrual fluid collected from normal and menorrhagic women. Br J Obstet Gynaecol. 1984;92:1164.
15. Sheppard B, Cockeray CJ, Bonnar J. An ultrastructural study of menstrual blood in normal menstruation and dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1983;90:259.
16. Adelanto JM, Rees CP, Bernal AL, et al. Increased uterine prostaglandin E receptors in menorrhagic women. Br J Obstet Gynaecol. 1988;95:162.
17. Smith SK, Abel MH, Kelly RW, et al. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1981;88:434.
18. Smith SK, Abel MH, Kelly RW, et al. A role for prostacyclin (PGI2) in excessive menstrual bleeding. Lancet. 1981;1:522-524.
19. Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas. 2003;45:1-14.
20. Rees MCP, Canete-Soler R, Lopez-Bernal A, et al. Effect of fenamates on prostaglandin E receptor binding. Lancet. 1998;ii:541-542.
21. Hickey M, Higham J, Fraser IS. Progestogens versus estrogens and progestogens for irregular uterine bleeding associated with an ovulation [Cochrane review]. In: The Cochrane Library. Issue 3. Chichester, UK: John Wiley & Sons, Ltd; 2004.
22. Conyngham RB. Norethisterone in menorrhagia. N Z Med J. 1965;64:697-701.
23. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynecol. 1990;30:352-356.
24. Cameron IT, Haining R, Lumsden MA, et al. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol. 1990;76:85-88.
25. Hingham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol. 1993;169:1134-1139.
26. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. The Cochrane Database of Systematic Reviews. Issue 4. 1998:CD001016.
27. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995;102:401-406.
28. Munro MG. Dysfunctional uterine bleeding: advances in diagnosis and treatment. Curr Opin Obstet Gynecol. 2001;13:475-489.
29. Sivin I, Stern J, Coutihno E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991;44:473-480.
30. Phillips V, Graham CT, Manek S, et al. The effects of the levonorgestrel intrauterine system (Mirena Coil) on endometrial morphology. J Clin Pathol. 2003;56:305-307.
31. Sheppard BL. Endometrial morphological changes in IUD users: a review. Contraception. 1987;36:1-10.
32. Barbosa I, Olsson SE, Odlind V, et al. Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept. 1995;11:85-95.
33. Pakarinen PI, Suvisaari J, Luukkained T, et al. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles. Fertil Steril. 1997;68:59-64.
34. Nilsson CG, Lähteenmäki P, Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception. 1980;21:225-233.
35. Barbosa I, Bakos O, Olsson SE, et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception. 1990;42:51-66.
36. Luukkainen T. The levonorgestrel-releasing IUD. Br J Fam Plann. 1993;19:221-224.
37. Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel- releasing intrauterine device. Ann Med. 1990;22:85-90.
38. Xiao B, Wu SC, Chong J, et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003;79:963-969.
39. Backman T, Huhtala S, Luoto R, et al. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol. 2002;99:608-613.
40. Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Contraception. 1987;35:245-255.
41. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-upstudy over 12 years of continuous use. Acta Obstet Gynecol Scand. 1999;78:716-721.
42. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49:56-72.
43. Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding [Cochrane review]. In: The Cochrane Library. Issue 3. Chichester, UK: John Wiley & Sons, Ltd; 2004.
44. Stewart A, Cummins C, Gold L, et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG. 2001;108:74-86.
45. Chi IC. The TCU- 380A (AG), MLCU375, and Nova-T IUDS and the IUD daily releasing 20 μg levonorgestrel-four pillars of IUD contraception for the nineties and beyond? Contraception. 1993;47:325-347.
46. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol. 1998;105:592-598.
47. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril. 2001;76:304-309.
48. Faundes A, Alvarez F, Brache V, et al. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gynaecol Obstet. 1988;26:429-433.
49. Starczewski A, Iwanicki M. [Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids]. Ginekol Pol. 2000;71:1221-1225.
50. Fong YF, Singh K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception. 1999;60:51-53.
51. Mercorio F, Simone RD, Sardo ADS, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception. 2003;67:277-280.
52. Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril. 1997;68:426-429.
53. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet. 2001;357:273-277.
54. Wolter-Svensson LO, Stadberg E, Andersson K, et al. Intrauterine administration of levonorgestrel 5 and 10 μg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstet Gynecol Scand. 1997;76:449-454.
55. Suhonen Sp, Holmstrom T, Allnone HO, et al. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril. 1995;63:336-342.
56. Andersson K, Mattsson LA, Rybo G, et al. Intrauterine release of levonorgestrel-a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol. 1992;79:96-97.
57. Gardner FJ, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomized controlled trial. Lancet. 2000;356:1711-1717.
58. Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651-657.
59. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164:879-883.
60. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception. 1995;51:231-235.
61. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990;97:690-694.
62. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol. 2002;57:120-128.
63. Cameron IT, Leask R, Kelly RW, et al. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins. 1987;34:99-110.
64. Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol. 1997;104:614-616.
65. Scholten PC, Christaens GCML, Haspels AA. Treatment of menorrhagia by intrauterine administration of levonorgestrel. In: Scholten PC, ed. The Levonorgestrel IUD: Clinical Performance and Impact on Menstruation [thesis]. Utrecht, The Netherlands: Utrecht University Hospital; 1989:47-55.
66. Crosignani PG, Vercellini P, Mosconi P et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obset Gynecol. 1997;90:257-263.
67. Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol. 2004;104:1314-1321.
68. Nagrani R, Bowen-Simpkins P, Barrington JW. Can the levonorgestrel intrauterine system replace surgical treatment for the management of menorrhagia? Br J Obstet Gynaecol. 2002;109:345-347.
69. Barrington JW, Arunkalaivanan AS, Abdel-Fattah M. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol. 2003;108:72-74.
70. Romer T. Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea. Eur J Obstet Gynecol Reprod Biol. 2000;90:27-29.
71. Lahteenmaki P, Haukkamaa M, Puokakka J, et al. Open randomized study of the use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ. 1998;316:1122-1126.
72. An evidence-based guideline for the management of heavy menstrual bleeding. Working Party for guidelines for the management of heavy menstrual bleeding. N Z Med J. 1999;112:174-177.
73. Marshall JK, Hunt RH. Hormonal therapy for bleeding gastrointestinal mucosal vascular abnormalities: a promising alternative, Eur J Gastroenterol Hepatol. 1997;9:521-525.
74. Daniell HW. Estrogen prevention of recurrent epistaxis [letter]. Arch Otolaryngol Head Neck Surg. 1995;121:354.
75. De Vore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding: a double blind randomized control study. Obstet Gynecol. 1982;59:285-291.
76. Shaw RW. Assessment of medical treatments for menorrhagia. Br J Obstet Gynaecol. 1994;101(Suppl 11):15-18.
77. Fraser IS, McCarron G. Randomized trial of 2 hormonal and prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynecol. 1991;31:66-70.
78. Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding [Cochrane review]. In: The Cochrane Library. Issue 4. Oxford: Update Software; 2002.
79. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000;96:913-920.
80. Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol. 1971;110:713-720.
81. Speroff L, Glass R, Kase N. Clinical Gynecologic Endocrinology and Infertility. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999.
82. Chimbria Th, Anderson ABM, Nalsh C, et al. Reduction of menstrual blood loss by Danazol in unexplained menorrhagia: lack of effect of placebo. Br J Obstet Gynaecol. 1980;87:1152-1158.
83. Beaumont H, Augood C, Duckitt K, et al. Danazol for heavy menstrual bleeding. In: The Cochrane Database of Systematic Reviews. Issue 2. 2002: CD001017.
84. Lamb MP. Danazol in menorrhagia: a double blind placebo controlled trial. J Obstet Gynecol. 1987;7:212-216.
85. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol. 1989;96:840-844.
86. Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1991;98:1155-1159.
87. Colacurci N, De Placido G, Mollo A, et al. Short-term use of Goserelin depot in the treatment of dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 1995;22:212-219.
88. Oehler MK, Rees MCP. Menorrhagia: an update. Acta Obstet Gynecol Scand. 2003;82:405-422.
89. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams & Wilkins, 1995.